We are committed to finding a cure for WM.

ibrutinib

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

Source: https://www.cancertherapyadvisor.com/hematologic-cancers/waldenstrom-macroglobulinemia-zanubrutinib-new-trial-treatment/article/801383/

A head-to-head, open-label, multicenter, phase 3 clinical trial comparing the efficacy and safety of zanubrutinib (BGB-3111) with ibrutinib in patients with Waldenström macroglobulinemia (WM) is underway (ClinicalTrials.org Identifier: NCT03053440).1 The study also seeks to evaluate the… Continue reading

Video: Dr. Dimopoulos Reflects on Ibrutinib Plus Rituximab in Waldenstrom Macroglobulinemia

Source: https://www.onclive.com/onclive-tv/dr-dimopoulos-reflects-on-ibrutinib-plus-rituximab-in-waldenstrom-macroglobulinemia

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients… Continue reading